MORF:NSD-Morphic Holding Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 34.07

Change

0.00 (0.00)%

Market Cap

USD 1.38B

Volume

2.14M

Analyst Target

USD 34.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.53 (+0.54%)

USD 120.95B
REGN Regeneron Pharmaceuticals Inc

+5.99 (+0.57%)

USD 115.81B
MRNA Moderna Inc

-2.80 (-2.36%)

USD 45.51B
ALNY Alnylam Pharmaceuticals Inc

+0.32 (+0.13%)

USD 28.20B
ARGX argenx NV ADR

+4.18 (+0.97%)

USD 26.78B
BNTX BioNTech SE

-1.53 (-1.90%)

USD 20.40B
GMAB Genmab AS

-0.28 (-1.11%)

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

-0.20 (-0.24%)

USD 15.98B
RPRX Royalty Pharma Plc

-0.18 (-0.68%)

USD 15.75B
BGNE BeiGene Ltd

+2.22 (+1.56%)

USD 15.73B

ETFs Containing MORF

BBC Virtus LifeSci Biotech Cl.. 1.11 % 0.79 %

+0.29 (+1.13%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.97% 76% C+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.97% 76% C+ 82% B
Trailing 12 Months  
Capital Gain -40.57% 44% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.57% 44% F 26% F
Trailing 5 Years  
Capital Gain 46.66% 80% B- 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 46.66% 80% B- 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 44.17% 85% B 89% A-
Dividend Return 44.17% 85% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 95.56% 27% F 16% F
Risk Adjusted Return 46.22% 92% A 77% C+
Market Capitalization 1.38B 85% B 76% C+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector